The role of global risk assessment in hypertension therapyLe rôle de l’évaluation globale du risque dans la thérapie de l’hypertension
References (25)
- et al.
Primary and subsequent coronary risk appraisal: New results from the Framingham study
Am Heart J
(2000) - et al.
Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy
Am J Cardiol
(2005) - et al.
The rudimentary phase of personalised medicine: Coronary risk scores
Lancet
(2003) - et al.
Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: Evidence based review
BMJ
(2001) - et al.
An updated coronary risk profile. A statement for health professionals
Circulation
(1991) - et al.
Estimating the benefits of modifying risk factors of cardiovascular disease: A comparison of primary vs secondary prevention
Arch Intern Med
(1998) - et al.
Lipoprotein-cholesterol distributions in selected North American populations: The lipid research clinics program prevalence study
Circulation
(1980) - et al.
Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation
JAMA
(2001) - et al.
Prediction of coronary heart disease using risk factor categories
Circulation
(1998) - et al.
The UKPDS risk engine: A model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
Clin Sci (Lond)
(2001)
Probability of stroke: A risk profile from the Framingham Study
Stroke
UKPDS: 60 Risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine
Stroke
Cited by (24)
2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
2016, Canadian Journal of CardiologyApplying Atherosclerotic Risk Prevention Guidelines to Elderly Patients: A Bridge Too Far?
2016, Canadian Journal of CardiologyCitation Excerpt :Finally, readily attainable personalized information comes from lifespan expectancy and biological age calculators, specifically those that have been validated to predict cardiovascular events. These calculators are typically on the basis of a synthesis of lifestyle and traditional risk drivers and can be effective incentive tools47 (www.projectbiglife.ca). Their role in guiding risk prevention strategies specifically in elderly patients warrants further attention.
The Challenges and Benefits of Cardiovascular Risk Assessment in Clinical Practice
2011, Canadian Journal of CardiologyCitation Excerpt :The Framingham model has been validated in a Canadian cohort. It has been shown to accurately forecast cardiovascular deaths in the Canadian Lipid Research Clinic (LRC) Follow-up Cohort without additional calibration.23 An online version is available (http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof).
Fibrinogen kinetics and protein turnover in hypertension: Effects of insulin
2009, Nutrition, Metabolism and Cardiovascular Diseases